Announcement PDF Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222 Neurizon Leadership Roundtable Webinar Reminder and Updated Investor Presentation Highlights:  Shareholders and interested investors are invited to join Neurizon’s Leadership Roundtable webinar featuring Neurizon’s recently appointed Chief Executive Officer, Dr Chris Bremer and members of the Company’s Board and Management team  The pre-recorded roundtable discussion will be followed by live Q&A, providing an opportunity to engage directly with management  Neurizon releases an updated Investor Presentation providing background information on the Company’s strategy, NUZ-001 and the foundations supporting its development 7 October 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) (“Neurizon” or “the Company”), a late clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to release its updated Investor Presentation and remind shareholders and interested investors of its upcoming Leadership Roundtable webinar. Updated Investor Presentation The updated presentation provides an overview of Neurizon’s strategy as the Company advances its lead investigational asset, NUZ-001, through late-stage clinical development. It highlights the 250-participant Phase 2/3 HEALEY ALS Platform Trial, with topline results expected in late Q2 CY2027, the clinical and scientific evidence generated to date, the NIH-funded Expanded Access Program, and the Company’s manufacturing, regulatory and commercial preparations ahead of the HEALEY readout. The Investor Presentation has been released as background information for shareholders and investors ahead of the roundtable. It is separate from the webinar and no slides will be presented during the event. Neurizon Leadership Roundtable Webinar – The Road Ahead The webinar will be held on Thursday, 8 October 2026 at 4:00pm AEDT and will feature a roundtable discussion with Neurizon’s Chief Executive Officer (CEO) Dr Chris Bremer, Non-Executive Chairman Sergio Duchini and Chief Finance Officer Dan O’Connell. The discussion will explore the Company’s recent progress, the advancement of NUZ-001 and Neurizon’s priorities for its next phase. The pre-recorded roundtable will be followed by a live Q&A, providing the opportunity to hear directly from the leadership team. Participants are encouraged to submit questions in advance via registration form or by emailing enquiries@neurizon.com.  Date: Thursday, 8 October 2026  Time: 4.00pm AEDT  Register: https://bit.ly/neurizonroundtable A recording of the roundtable discussion will be made available following the event. -ENDS- This announcement has been authorised for release by Dr Chris Bremer, Chief Executive Officer of Neurizon Therapeutics Limited. For further information, please contact: Marketing & Corporate Affairs Lidija Damjanovic Email: lidija@neurizon.com Phone: +61 (0) 425 700 504 Investor Relations Henry Jordan Email: henry.jordan@sdir.com.au Phone: +61 (0) 431 271 538 Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222 About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a late clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical program, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction. Neurizon Investor Hub We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements. To access Neurizon Investor Hub please scan the QR code or visit https://investorhub.neurizon.com Neurizon® is a registered trademark of Neurizon Therapeutics Limited ABN 35 094 006 023 Advancing NUZ-001 in ALS towards a key clinical readout Investor Presentation - October 2026 2 Disclaimer This disclaimer applies to this presentation and the information contained in it (This presentation has been prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the “Company”)). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters. No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation. This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so). Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company. Future Matters This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended. US Disclosure This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers. Investor Presentation - October 2026 Our Vision To lead the development of treatments towards a promising new horizon for people living with neurodegenerative diseases. Neurizon: A late clinical-stage biotech developing therapies for neurodegenerative diseases 4 Lead ALS/MND program in Phase 2/3, with topline results expected in late Q2 CY2027 WHO WE ARE Neurizon is developing therapies for neurodegenerative diseases, with its lead investigational therapy, NUZ-001, currently being evaluated in ALS/MND. NUZ-001 is an oral small molecule with preclinical evidence demonstrating effects on cellular protein clearance pathways associated with neurodegeneration. ASX: NUZ · OTCQB: NUZTF LEAD ASSET: NUZ-001 Investigational oral small molecule being developed initially in ALS/MND and currently evaluated in the Phase 2/3 HEALEY ALS Platform Trial. NUZ-001 IN ALS/MND AT A GLANCE ORAL Once-daily administration PHASE 2/3 HEALEY ALS Platform Trial 250 Regimen I participants, randomised 3:1 LATE Q2 2027 Expected topline BUILT AROUND THE CLINICAL OPPORTUNITY CLINICAL VALIDATION 250-participant Phase 2/3 HEALEY API SUPPLY ESTABLISHED Long-term supply agreement with Elanco EXPANDED EVIDENCE NIH-funded EAP up to 200 participants NEAR-TERM CATALYST Topline expected late Q2 CY2027 BROADER POTENTIAL Preclinical evidence in other neurodegenerative diseases Investor Presentation - October 2026 Why look now 5 A randomised Phase 2/3 readout in late Q2 2027 is the next value inflection Late Q2 2027 Expected topline from the 250- participant Phase 2/3 ALS trial. Enrolled Under 5 Months A record for the HEALEY ALS Platform Trial. Clinical advancement A 250-participant randomised Phase 2/3 enrolled in less than 5 months – record enrolment for the HEALEY ALS Platform Trial. NIH-funded EAP for NUZ-001 Evidence-led development Promising Phase 1 signals, with an exploratory biomarker panel (including NfL and TDP-43) built into ongoing Phase 2/3 trial. HEALEY provides established clinical infrastructure across 78 US sites led by Mass General Brigham. Supply chain readiness for scale Long-term supply agreement with Elanco for GMP API supply and registration-scale manufacturing. Strategic and commercial optionality An upcoming, randomised Phase 2/3 dataset that will inform Neurizon’s regulatory, partnering and commercial strategy. Total addressable market (TAM) opportunity of ~US$5bn1 1 3 2 4 NIH-Funded EAP for NUZ-001 for 200 participants up to 96 weeks. 1 Illustrative US TAM of approximately US$5 billion based on projected 2026 US ALS prevalence of approximately 34,720 adults (CDC National ALS Registry) and assumed annual net pricing of US$150,000 per patient. Investor Presentation - October 2026 Leadership for the next stage 6 Dr Chris Bremer commencing as Chief Executive Officer on 1 October 2026 Investor Presentation - October 2026 CHIEF EXECUTIVE OFFICER Dr Chris Bremer Effective 1 October 2026. Leads Neurizon through the HEALEY readout and the decisions that follow. CLINICAL DEVELOPMENT John Clark · Amanda Seiz · Dr Chris Freitag SCIENCE AND REGULATORY Dr Martin Engel · Linda McBride FINANCE AND CORPORATE Dan O’Connell · Sergio Duchini EXPERIENCED BOARD Dr Ross Murdoch, Dr Katie MacFarlane, Marcus Hughes, Dr Steve Nanchen (Elanco, Observer) DRAWING ON DEEP SECTOR EXPERIENCE: EXPERIENCE TO LEAD THE NEXT PHASE 20+ years of global biopharmaceutical leadership SCIENCE STRATEGY TRANSACTIONS Drug development Portfolio & commercialisation Licensing & Partnerships MD | PhD | MBA | INSEAD 7 NUZ-001: from scientific origin to clinical execution From an established veterinary molecule to a randomised Phase 2/3 in ALS NUZ-001 is a well-characterised molecule, with novel neurodegenerative biology, now advancing through a Phase 2/3 ALS clinical programme Investor Presentation - October 2026 2005 - 2023 1 Translation to human disease and Neurizon formation • Monepantel: proven veterinary drug with deep safety data • Moved from veterinary use into neurodegeneration • Neurizon formed as a focused neurodegeneration company 2024 – 2025 2 Clinical validation and HEALEY selection • NUZ-001 Phase 1 showed encouraging signals across exploratory clinical measures in people with ALS • Results drove inclusion in the HEALEY ALS Platform Trial • 78 US sites, led by Mass General Brigham NOW TO LATE Q2 2027 3 Clinical execution • Phase 2/3 HEALEY trial in active execution • Topline results expected late Q2 2027 • Treatment appeared safe and generally well tolerated. About ALS ALS contributes to progressive degeneration of motor neurons, leading to increasing loss of voluntary muscle function ALS AT A GLANCE 2–5 YEARS Typical life expectancy following diagnosis* ~90% of ALS cases are without family history NO CURE Significant unmet medical need remains ~35,000 people living with ALS in the US1 No approved therapy has substantially altered the course of ALS progression for the broad patient population. A therapy that slows ALS meaningfully, in a broad population, with oral dosing, would address a substantial need in the ALS/MND market. *Disease course varies considerably between individuals. Sources for final deck: ALS Association / peer-reviewed literature; verify wording and citations before publication. .1. US prevalence estimate as used in company materials. SPEECH Loss of ability to speak SWALLOWING Increasing difficulty swallowing MOVEMENT Progressive loss of muscle function BREATHNG Increasing difficulty breathing ALS is a rapidly progressive neurodegenerative disease with significant unmet need 9 Investor Presentation - October 2026 10 FUS = Fused in Sarcoma; SOD1 = Superoxide Dismustase 1; TDP-43 = Transactive response DNA-binding protein 43 1. Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013 Aug 7;79(3):416-38. doi: 10.1016/j.neuron.2013.07.033. In most ALS/MND, nuclear TDP-43 is lost and accumulates in the cytoplasm, disrupting RNA processing, axonal maintenance and communication with muscles TDP-43 dysfunction & aggregation links ALS pathology to motor neuron failure Investor Presentation - October 2026 1 2 3 <1% FUS Mutation ~2% SOD1 Mutation 97% TDP-43 Aggregation A SHARED PATHOLOGY of ALS cases show TDP-43 pathology1 TDP-43 IS LOST FROM THE NUCLEUS AND BUILDS UP IN THE CELL Nuclear TDP-43 Loss Cellular TDP-43 Aggregation The neuron loses normal function while harmful protein burden increases. THE MOTOR NEURON–MUSCLE CONNECTION BREAKS DOWN A B C Impaired axon maintenance and synaptic vesicle release Æ unreliable muscle control Cytoplasmic toxic aggregates trap essential proteins Æ impair axon transport Cytoplasmic aggregates stress cellular machinery Æ starve motor neurons NUZ-001 shown in preclinical studies to enhance cellular protein clearance mechanisms to support motor neuron proteostasis A B C ALS: high unmet need with significant value potential 11 Three decades of approvals have delivered limited clinical benefit Key ALS Value Reference Point: Shionogi – RADICAVA (2026) US$2.5B Upfront for global rights paid by Shionogi to Tanabe Pharma ~US$700M Expected annual global sales • Commercial, revenue-generating ALS franchise • Oral product US patent until 2039 • Rare disease commercial platform foundation Current US ALS treatment landscape 2017 IV 2022 ORAL RILUZOLE Broad ALS population | Oral RADICAVA® / RADICAVA ORS® Broad ALS population | IV & oral QALSODY® SOD1-ALS only | Intrathecal 1995 2023 ~3 months median survival extension across randomized controlled trials ~6 months median survival extension across randomized controlled trials ~3 years median survival extension in pivotal VALOR trial Protects neurons from overactivation-induced death Reduces neuron degeneration as antioxidant in the nervous system Binds to mRNA of SOD1 to prevent toxic protein cluster formation in neurons 1 2 3 4 1. Hinchcliffe et al. 2017, Degenerative Neurological and Neuromuscular Disease 7 (May): 61–70. 2. Takahashi et al. 2025, Muscle & Nerve 72 (4): 586–96. 3. Miller et al. 2026 JAMA Neurology 83 (2): 115–25. 4. Shionogi press release, 22 December 2025; transaction completion announced April 2026 Investor Presentation - October 2026 Science Behind NUZ-001 Therapeutic Approaches Addressing ALS Biology 13 Addressing cellular quality-control systems involved in clearing toxic protein aggregates. Protein Homeostasis Gene-Targeting & RNA Modulation Silencing or correcting disease- causing gene transcripts at the RNA level. Dampening toxic glial activation and immune-driven neuron injury. Neuroinflammation & Immune Regulation Neutralise toxic free radicals and protect vital cellular components. Oxidative Stress Gene translation Investor Presentation – October 2026 Pre-clinical Evidence Supporting NUZ-001 Potential in ALS/MND 14 Prevents cellular TDP-43 aggregation Enhances protein clearance mechanisms (autophagy & proteosomal system) Preserves STMN2 expression to support neuronal health Restores NfL axonal health and synaptic signalling + NUZ-001 NfL = Neurofilament Light, STMN2 = Stathmin-2; TDP-43 = Transactive response DNA-binding protein 43 Consistent effects observed across models: MND-patient motor neurons Zebrafish Human neurospheres NUZ-001 Enhances Protein Clearance Pathways to Remove Toxic Protein Aggregates Investor Presentation – October 2026 NUZ-001 Expansion potential : Platform Optionality for Proteinopathy-Driven Diseases 15 TDP-43 ALS/AD/PD/FTD/CTE Amyloid beta AD/PD Tau AD/PD/FTD/CTE/PSP alpha Synuclein AD/PD NUZ-001 is a mechanism-driven, disease-agnostic approach to treating neurodegeneration by rebalancing proteostasis and addressing core cellular dysfunction. AD = Alzheimer’s Disease; ALS = Amyotrophic Lateral Sclerosis; CTE = Chronic Traumatic Encephalopathy; FTD = Frontotemporal Dementia; HD = Huntington Disease; PD = Parkinson’s Disease; PSP = Progressive Supranuclear Palsy Strong mechanistic rationale for potential efficacy across a wide array of neurodegenerative diseases. Impaired proteostasis contributes to the formation of intracellular inclusion bodies of misfolded proteins, a hallmark of neurodegenerative diseases. mHTT HD New preclinical data show NUZ-001 increases activity of multiple protein clearance pathways in neuronal models: autophagy and proteasomal systems. Investor Presentation – October 2026 Clinical Development Phase 1b and Open Label Extension Study Early Clinical Development of NUZ-001 in MND/ALS started in Australia 17 PRIMARY OUTCOME • Long-term treatment with NUZ-001 at the recommended Phase 2/3 dose appeared safe and generally well-tolerated (n=12) SLOWED FUNCTIONAL DECLINE RESPIRATORY STABILISATION SURVIVAL* • Sustained slowing in disease progression by 39% (P1b) and 31% (P1b & OLE) compared to PRO-ACT matched controls • No study discontinuations • Several participants still accessing NUZ- 001 under the TGA’s Special Access Scheme Highlights (Based on a study population of n=12 patients) • Reduction in the risk of death by 71% compared to PRO-ACT matched controls • Estimated life extension of ~16 months • 49% reduction (P1b) and 43% reduction (P1b & OLE) in VC PP compared to PRO- ACT matched controls * Neurizon Phase 1 and Open Label Extension Study data from September 2025 BIOMARKER TRENDS • Stable plasma NfL and urinary p75ECD PATIENT SATISFACTION Investor Presentation – October 2026 -2.93 -1.65 -5 -4.5 -4 -3.5 -3 -2.5 -2 -1.5 -1 -0.5 0 PRO-ACT Matched Controls (n=420) NUZ-001 (n=12) -1.21 -0.83 -2 -1.8 -1.6 -1.4 -1.2 -1 -0.8 -0.6 -0.4 -0.2 0 PRO-ACT Matched Controls (n=360) NUZ-001 (n=12) ALSFRS-R Slope (points/month) Phase 1b and Open Label Extension Results Preliminary Signals of Efficacy in ALSFRS-R and SVC 18 Treatment with NUZ-001 across combined Phase 1 and OLE studies slowed the progression of ALS in all patients by 31% for ALSFRS-R and 43% for SVC percent predicted (PP) when compared to matched controls from the PRO-ACT historical database1 1. Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I, Schoenfeld D, Cudkowicz M, Leitner M. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014 Nov 4;83(19):1719-25. doi: 10.1212/WNL.0000000000000951.Epub 2014 Oct 8. PMID: 25298304; PMCID: PMC4239834 2. Forced vital capacity (FVC) was used when SVC was not collected 3. Matched on time since onset, baseline ALSFRS-R, pre-baseline slope, and disease onset location Motor Function – ALSFRS-R Difference 0.37 points/month (p=0.145) Difference 1.27 points/month (p=0.078) 31% 43% Respiration – SVC PP2 3 3 VC PP Slope (points/month) Investor Presentation – October 2026 Phase 1b & Open Label Extension NUZ-001 shows improved survival vs matched controls 19 NUZ-001 treatment resulted in statistically significantly longer survival of participants with ALS, (X2=11.35, p=0.00075), compared to matched controls1 from the PRO-ACT database2 1. Matched on time since onset, baseline ALSFRS-R, pre-baseline ALSFRS-R slope, and disease onset location 2. Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I, Schoenfeld D, Cudkowicz M, Leitner M. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014 Nov 4;83(19):1719-25. doi: 10.1212/WNL.0000000000000951.Epub 2014 Oct 8. PMID: 25298304; PMCID: PMC4239834 Analysis* suggests that treatment with NUZ-001 reduces the risk of death by 71%: Hazard ratio of 0.29 (95% CI: (0.131, 0.644), p = 0.0024) Investor Presentation – October 2026 * Neurizon Phase 1 and Open Label Extension Study data from September 2025 Clinical development progress from Phase 1b to Phase 2/3 20 Phase 1b established preliminary safety profile & informed the hypothesis; HEALEY is designed to provide the controlled evidence Investor Presentation – October 2026 NUZ-001 was selected for inclusion in HEALEY following independent ALS expert review of Neurizon’s preclinical and clinical evidence package. Phase 1b Foundation in 12 People Living with ALS • Established 10 mg/kg daily dose • Preliminary safety profile observed over 3.5 years • Early signals of efficacy; slowing function decline and extended life expectancy • Mechanistic insights for hypothesis-formation & trial design HEALEY PROVIDES THE EVIDENCE Tailored Study Design Randomised • double-blind • concurrent placebo • 36 weeks SCALE + EXECUTION 250 Participants 78 US sites under a single master protocol <5 months to complete enrolment Filing-relevant evidence package Function • survival • extended safety • CSF exposure • biomarkers Clinical Questions to be Determined • Clinical efficacy against matched placebo • Reproducibility across MND/ALS diversity • Biological measures of disease progression Regimen I is designed to investigate clinical benefit 21 REGIMEN I AT A GLANCE Design Double-blind, placebo-controlled adaptive Phase 2/3 under the HEALEY master protocol Participants 250 enrolled at close of recruitment (protocol expanded from 160 to 240 in May 2026) Randomisation 3:1 NUZ-001 to placebo — a fully concurrent, internally consistent placebo arm Dose and route 10 mg/kg once daily, oral — the dose carried forward from the Phase 1b open-label extension Treatment period 36-week double-blind period, followed by a 36-week active treatment extension 36-week blinded period Earlier HEALEY regimens read out at 24 weeks. A longer blinded window gives more time for functional curves to separate in a disease where treatment effects accumulate slowly and variably, and optimises the chance of showing a clinically meaningful treatment effect. Fully concurrent placebo arm Regimen I carries its own placebo group, removing the temporal-drift and comparability associated with pooled placebos. Primary and Secondary Endpoints WHY THESE DESIGN CHOICES MATTER Recruitment complete July CY2026 All participants enrolled and dosing commenced RCT Completion Early Q2 CY2027 36-week randomised period, then active extension Database lock Q2 CY2027 Data cleaning and validation Topline result Late Q2 CY2027 Primary efficacy and safety readout P: Change in ALSFRS-R and survival from baseline to Week 36 S: Slow vital capacity from baseline to Week 36 S: Freedom from death or permanent assisted ventilation from baseline to Week 36 Investor Presentation – October 2026 Exploratory Endpoints Biological validation of disease progression and mechanism of action through extensive exploratory biomarker panel (NfL, mtDNA, protein panel, speech) Regimen I Biomarker Portfolio 22 Connecting clinical response profile with biological measures provides development optionality Investor Presentation – October 2026 Blood / CSF response to disease and treatment Molecular analysis - disease activity and treatment mechanism Digital speech - objective signal of disease progression Biomarker Insight Identify subgroups Clarify who may benefit most in a heterogeneous disease Support regulatory dialogue Add biological context to the totality of evidence De-risk future development Inform population selection and next- study design Inform future payer discussions Build evidence for differentiated value and access HEALEY Regimen I Large, diverse, well- characterised ALS population Expanded access protocol extends NUZ-001 to patients outside Regimen I 23 What the program does Why it matters Access outside the trial Provides NUZ-001 to people with ALS who cannot access Regimen I. Funded externally NIH funded, highlighting further program validation. Access is extended without drawing on capital allocated to HEALEY. ✓ Operates alongside the RCT Separate from Regimen I; no effect on its conduct, randomisation or blinding. Observations are uncontrolled and are not evidence of efficacy. Investor Presentation – October 2026 Why it matters HEALEY REGIMEN I (RCT) Randomised, blinded, 3:1 36-week blinded period, placebo controlled Topline late Q2 CY2027 EXPANDED ACCESS PROTOCOL (EAP) NIH-funded, non-dilutive Broader patient population, all on active Observations without placebo control WHAT THE EAP ADDS TO THE PROGRAM Longer-term safety in a broader population Grant-funded drug supply and safety systems Wider clinician experience with NUZ-001 EAP is complementary to HEALEY RCT and fully funded by US National Institute of Health (NIH) ✓ ✓ The Road Ahead Comparison of Key Outcomes Across Approved ALS Treatments & NUZ-001 Riluzole1 (Rilutek®) Edaravone2 (Radicava®) Amx00353,4 (Relyvrio®) Tofersen6 (Qalsody®) 01 02 03 04 ALSFRS-R (Improvement Compared to Placebo) Not evaluated Not evaluated FVC/SVC (Improvement Compared to Placebo) Survival (Improvement Compared to Placebo) NUZ-0017 ~3 months 33.20% (p=0.0013) 23.43% (FVC, p=0.0942) ~6 months 23.27% (p=0.030) 22.37% (SVC, p=0.080) ~6.5 months5 14.74% (p=0.970) 35.59% (SVC, p>0.05) Not evaluated 39% (p=0.080)10 48% (SVC, p=0.058)10 31% (p=0.145)10 41% (SVC, p=0.078)10 ~16 months10 24 weeks 24 weeks 28 weeks OLE: 116 weeks9 MEND: 40 weeks8 1. N Engl J Med. 1994 Mar 3;330(9):585–9;2. Lancet Neurol 201716: 505-12; 3. N Engl J Med 2020; 383:919-30; 4. Voluntary removal from the market; 5. Muscle Nerve. 2021 Apr;63(4):31–39.6. Engl J Med 2022:387:1099-110; 7. Neurizon data on file; 8. Median treatment period in Phase 1 MEND Study; 9. Median treatment period for combined Phase 1 MEND Study and OLE Study; 10. Comparison to matched untreated controls in PRO-ACT Database. 11. Research Reports World 2024; 12. BioPharma Dive, ALS Drug Development, September 30, 2025; 13. Biogen 2025 Annual Report; Verified Market Report 2025; (2017) (1995) (2022) (2023) Cross-trial comparisons are descriptive only; differences in study design, patient populations, and endpoints limit direct comparability. 52 weeks n=77 n=69 n=89 n=72 n=12 Investigational 25 Investor Presentation - October 2026 Annual Sales Generic, ~US$40m in sales11 ~US$1 bn in peak sales11 >US$400m sales12 ~US$86.9m sales13 NA A Trial Pathway Built To Carry Advanced Regulatory Discussion 26 Potential pathway options only. Final strategy, approval pathway and label depend on the Regimen I trial data and regulator interaction. Investor Presentation - October 2026 UNDER WAY Blinded treatment 36-week randomised period, then an active treatment extension LATE Q2 CY2027 Phase 2/3 readout Function, survival, respiratory, safety and biomarker data across all participants and pre-specified subgroups FOLLOWING READOUT Agency engagement Discussion with the FDA, EMA, TGA and PMDA on the data package SUBJECT TO DATA Registration path Scope, route and timing are set in the regulatory engagement. WHAT REGIMEN I BRINGS INTO THAT DISCUSSION A randomised, internally controlled dataset Regimen I carries its own concurrent placebo arm rather than pooled platform controls, over a longer duration vs other regimens. Supporting evidence built alongside the trial An exploratory biomarker panel and real-world data from the Expanded Access Program to support data from the primary and secondary endpoints. Regulatory and manufacturing readiness Orphan drug desi